Security
Actinium Pharmaceuticals, Inc · ATNM
ATNMNYSE_AMERICANCommon stockCurrentCIK 1388320Updated Nov 17, 2026
ATNM price & chart
Loading TradingView…
AMEX:ATNM on TradingView ↗About the company
Actinium is a pioneer in targeted radiotherapies designed to improve outcomes for patients with cancer. The company employs a biology-driven approach to develop differentiated radiopharmaceuticals for solid tumors and hematologic malignancies. Its mission is to transform cancer treatment through innovative radioconjugates that maximize therapeutic efficacy while minimizing toxicity to healthy tissue by combining expertise in tumor biology, translational medicine, and radiochemistry. Since inception, Actinium has focused on developing innovative radiotherapies. Its pipeline reflects this strategy across three areas: (1) solid tumor therapeutics including ATNM-400 and Actimab-A with pan-tumor potential; (2) Actimab-A as a therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in collaboration with the National Cancer Institute (NCI); and (3) targeted conditioning agents including Iomab-B for bone marrow transplant and Iomab-ACT for cell and gene therapy conditioning. ATNM-400 targets a novel antigen distinct from PSMA and has demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (…
In the news
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM News provided by The Gross Law Firm May 22, 2025, 05:45 ET Share this article Share to X Share this article Share to X NEW YORK , May 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the ↗
Recent filings
10-Q filing
ARS filing
DEF 14A filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
S-8 filing
Show 5 more recent filings
4 filing
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Regulation FD Disclosure
Items 3.01, 7.01, 9.01
10-Q filing
Other Events
Items 8.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Regulation FD Disclosure
Items 3.01, 7.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 56,151,000Source | 82,114,000Source | 40,157,000Source | 63,017,000Source | 89,861,000Source | 45,438,000Source | 68,647,000Source | 88,352,000Source | 51,775,000Source | 76,899,000Source | 81,445,000Source | 114,192,000Source |
| Property, Plant and Equipment, NetUSD | 226,000Source | 412,000Source | 700,000Source | 271,000Source | 460,000Source | 268,000Source | 317,000Source | 496,000Source | 295,000Source | 364,000Source | 550,000Source | 604,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 53,391,000Source | 78,660,000Source | 36,473,000Source | 59,928,000Source | 86,037,000Source | 42,132,000Source | 65,325,000Source | 84,057,000Source | 47,998,000Source | 72,904,000Source | 76,677,000Source | 108,910,000Source |
| Assets, CurrentUSD | 54,366,000Source | 79,520,000Source | 37,740,000Source | 61,029,000Source | 87,068,000Source | 43,261,000Source | 66,456,000Source | 85,373,000Source | 49,381,000Source | 74,506,000Source | 78,263,000Source | 110,942,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 975,000Source | 860,000Source | 1,267,000Source | 1,101,000Source | 1,031,000Source | 1,129,000Source | 1,131,000Source | 1,316,000Source | 1,383,000Source | 1,602,000Source | 1,586,000Source | 1,636,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,215,000Source | 1,838,000Source | 1,373,000Source | 1,373,000Source | 1,990,000Source | 1,565,000Source | 1,530,000Source | 2,140,000Source | 1,754,000Source | 1,685,000Source | 2,289,000Source | 2,341,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 42,367,000Source | 43,906,000Source | 9,855,000Source | 44,004,000Source | 46,026,000Source | 43,134,000Source | 42,953,000Source | 44,495,000Source | 43,941,000Source | 44,141,000Source | 45,066,000Source | 47,711,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 31,000Source | 31,000Source | 31,000Source | 31,000Source | 31,000Source | 31,000Source | 31,000Source | 29,000Source | 31,000Source | 31,000Source | 28,000Source | 26,000Source |
| Additional Paid in CapitalUSD | 417,526,000Source | 407,351,000Source | 417,665,000Source | 417,624,000Source | 401,410,000Source | 417,547,000Source | 417,427,000Source | 390,081,000Source | 417,536,000Source | 408,553,000Source | 373,934,000Source | 355,220,000Source |
| Retained Earnings (Accumulated Deficit)USD | -403,773,000Source | -369,174,000Source | -387,334,000Source | -398,642,000Source | -357,606,000Source | -415,235,000Source | -391,764,000Source | -346,253,000Source | -409,713,000Source | -375,826,000Source | -337,583,000Source | -288,765,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | -60,000Source | — | — | -39,000Source | — | — | -20,000Source | — | — | — |
| Stockholders' Equity Attributable to ParentUSD | 13,784,000Source | 38,208,000Source | 30,302,000Source | 19,013,000Source | 43,835,000Source | 2,304,000Source | 25,694,000Source | 43,857,000Source | 7,834,000Source | 32,758,000Source | 36,379,000Source | 66,481,000Source |
| Liabilities and EquityUSD | 56,151,000Source | 82,114,000Source | 40,157,000Source | 63,017,000Source | 89,861,000Source | 45,438,000Source | 68,647,000Source | 88,352,000Source | 51,775,000Source | 76,899,000Source | 81,445,000Source | 114,192,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 6,834,000Source | 7,755,000Source | 9,260,000Source | 8,314,000Source | 9,728,000Source | 7,349,000Source | 7,110,000Source | 8,064,000Source | 7,969,000Source | 8,148,000Source | 8,494,000Source | 10,628,000Source |
| Operating Lease, Liability, CurrentUSD | 599,000Source | 549,000Source | 741,000Source | 589,000Source | 540,000Source | 726,000Source | 579,000Source | 540,000Source | 711,000Source | 569,000Source | 530,000Source | 494,000Source |
| Operating Lease, Liability, NoncurrentUSD | 531,000Source | 1,139,000Source | 595,000Source | 685,000Source | 1,284,000Source | 785,000Source | 836,000Source | 1,414,000Source | 972,000Source | 984,000Source | 1,553,000Source | — |
| Additional Financial Items | ||||||||||||
| Deferred Revenue, NoncurrentUSD | — | — | — | — | — | — | — | 35,000,000Source | — | — | 35,000,000Source | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 29,000Source | 47,000Source | 173,000Source | 197,000Source | 790,000Source | 699,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 11,000Source | 8,874,000Source | 9,190,000Source | 5,292,000Source | 3,842,000Source | 2,795,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -5,870,000Source | -7,574,000Source | -24,580,000Source | -33,072,000Source | -47,335,000Source | 8,644,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -2,000Source | — | -104,000Source | -11,000Source | -153,000Source | -366,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 2,000Source | — | 104,000Source | 11,000Source | 153,000Source | 366,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | — | 207,000Source | — | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -3,000Source | -2,000Source | -217,000Source | 29,321,000Source | 14,870,000Source | 23,109,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -5,864,000Source | -7,576,000Source | -24,895,000Source | — | — | 31,387,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 53,723,000Source | 78,982,000Source | 36,812,000Source | 60,257,000Source | 42,469,000Source | 65,652,000Source | 48,333,000Source | 73,228,000Source | 76,990,000Source | 109,608,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | 11,000Source | — | 6,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 6,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 173,000Source | 197,000Source | 207,000Source | 152,000Source |
| General and Administrative ExpenseUSD | — | — | 1,534,000Source | 2,827,000Source | 2,058,000Source | 2,624,000Source | 1,702,000Source | 8,938,000Source | 15,213,000Source | 12,076,000Source | 13,331,000Source | 11,999,000Source |
| Investment Income, InterestUSD | — | — | 561,000Source | 1,033,000Source | 336,000Source | 625,000Source | 381,000Source | 700,000Source | 2,360,000Source | 3,878,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -5,131,000Source | -11,568,000Source | 27,901,000Source | -6,878,000Source | -5,522,000Source | -15,938,000Source | -33,887,000Source | -38,243,000Source | -48,818,000Source | -33,017,000Source |
| Nonoperating Income (Expense)USD | — | — | 561,000Source | 1,033,000Source | 336,000Source | 625,000Source | 381,000Source | 700,000Source | 2,360,000Source | 3,878,000Source | 3,102,000Source | 1,087,000Source |
| Operating ExpensesUSD | — | — | 5,782,000Source | 12,601,000Source | 7,435,000Source | 7,503,000Source | 5,903,000Source | 16,638,000Source | 36,337,000Source | 42,121,000Source | 52,001,000Source | 35,134,000Source |
| Operating Lease, ExpenseUSD | — | — | 173,000Source | 173,000Source | 218,000Source | 173,000Source | 218,000Source | 173,000Source | 707,000Source | 691,000Source | 691,000Source | 584,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | 29,255,000Source | 14,612,000Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | 75,000Source | 262,000Source | — |
| Revenue from Contract with Customer, Including Assessed Tax | — | — | — | — | —Source | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 90,000Source | — | 35,000,000Source | — | — | — | 90,000Source | — | 81,000Source | 1,030,000Source |
| Operating Income (Loss)USD | — | — | -5,692,000Source | -12,601,000Source | 27,565,000Source | -7,503,000Source | -5,903,000Source | -16,638,000Source | -36,247,000Source | -42,121,000Source | -51,920,000Source | -34,104,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -5,131,000Source | -11,568,000Source | 27,901,000Source | -6,878,000Source | -5,522,000Source | -15,938,000Source | -33,887,000Source | -38,243,000Source | -48,818,000Source | -33,017,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.16Source | -0.37Source | 0.89Source | -0.22Source | -0.18Source | -0.51Source | -1.09Source | -1.27Source | -1.83Source | -1.37Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.16Source | -0.37Source | 0.89Source | -0.22Source | -0.18Source | -0.51Source | -1.09Source | -1.27Source | -1.83Source | -1.37Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 31,195,891Source | 31,071,297Source | 31,399,086Source | 31,195,891Source | 31,237,681Source | 31,195,891Source | 31,195,891Source | 30,070,028Source | 26,604,045Source | 24,141,545Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 31,195,891Source | 31,071,297Source | 31,406,740Source | 31,195,891Source | 31,237,681Source | 31,195,891Source | 31,195,891Source | 30,070,028Source | 26,604,045Source | 24,141,545Source |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | — | — | — | 197,000Source | 790,000Source | 699,000Source |
| General and Administrative ExpenseUSD | — | — | 1,534,000Source | 2,827,000Source | 2,058,000Source | 2,624,000Source | 1,702,000Source | 8,938,000Source | 15,213,000Source | 12,076,000Source | 13,331,000Source | 11,999,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -33,289,000Source | — | — | — |
| Interest Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | 3,102,000Source | 1,087,000Source |
| Investment Income, InterestUSD | — | — | 561,000Source | 1,033,000Source | 336,000Source | 625,000Source | 381,000Source | 700,000Source | 2,360,000Source | 3,878,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | 561,000Source | 1,033,000Source | 336,000Source | 625,000Source | 381,000Source | 700,000Source | 2,360,000Source | 3,878,000Source | 3,102,000Source | 1,087,000Source |
| Operating ExpensesUSD | — | — | 5,782,000Source | 12,601,000Source | 7,435,000Source | 7,503,000Source | 5,903,000Source | 16,638,000Source | 36,337,000Source | 42,121,000Source | 52,001,000Source | 35,134,000Source |
| Operating Lease, ExpenseUSD | — | — | 173,000Source | 173,000Source | 218,000Source | 173,000Source | 218,000Source | 173,000Source | 707,000Source | 691,000Source | 691,000Source | 584,000Source |
| Other IncomeUSD | — | — | — | — | — | — | — | — | — | — | 100,000Source | — |
| Research and Development ExpenseUSD | — | — | 4,248,000Source | 9,774,000Source | 5,377,000Source | 4,879,000Source | 4,201,000Source | 7,700,000Source | 21,124,000Source | 30,045,000Source | 38,670,000Source | 23,135,000Source |
| Revenue from Contract with Customer, Including Assessed Tax | — | — | — | — | —Source | — | — | — | — | — | — | — |
Filing attachments
ea030877001ex99-1.htm · 10-Q · 2026-11-16
Exhibit 99.1 Novartis Pharmaceuticals Corporation One Health Plaza East Hanover, NJ 07936-1080 Robert Stanley Head US Legal & Global Legal Innovation robert.stanley@novartis.com July 31, 2026 Paul Diamond, Ph. D. Vice President, Legal and Intellectual Property Counsel Actinium Pharmaceuticals, Inc. 100 Park Avenue, 23rd Floor New York, NY 10017 pdiamond@actiniumpharma.com Dear Dr. Diamond: I am writing on behalf of Novartis Pharmaceuticals Corporation (“Novartis”) to repea…
Read attachment ↗ea030854201ex99-1.htm · 8-K · 2026-10-15
Exhibit 99.1 Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer NEW YORK, October 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (“Actinium” or the “Company”), a pioneer in the development of targeted radiotherapies, today announced the appointment of Matt David, M.D., as Chief Financial Officer. Dr. David will lead the Company’s finance, accounting, capital markets and investor relations functions…
Read attachment ↗ea030189001ex99-1.htm · 8-K · 2026-08-14
EX-99.1 2 ea030189001ex99-1.htm PRESS RELEASE DATED AUGUST 14, 2026 Exhibit 99.1 Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update NEW YORK, August 14, 2026 /PRNewswire/ - Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced advances across its Actimab-A program, including recently acquired patents adding …
Read attachment ↗ea029269101ex99-1.htm · 8-K · 2026-05-29
EX-99.1 2 ea029269101ex99-1.htm PRESS RELEASE DATED MAY 29, 2026 Exhibit 99.1 Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice NEW YORK, May 29, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced it will provide a program update on its first-in-class Actinium-225 (22…
Read attachment ↗